Document is current
Any future updates will be listed below
-
Authors
Abbott, Keene L. https://orcid.org/0000-0002-6166-704X
Subudhi, Sonu https://orcid.org/0000-0002-5937-1880
Ferreira, Raphael https://orcid.org/0000-0001-9881-6232
Gültekin, Yetiş
Steinbuch, Sophie C.
Munim, Muhammad Bin
Ramesh, Diya L. https://orcid.org/0009-0009-4255-6967
Honeder, Sophie E. https://orcid.org/0000-0002-7201-6293
Kumar, Ashwin S.
Wu, Michelle https://orcid.org/0009-0001-8120-6072
Hansen, Jacob A.
Shevzov-Zebrun, Anna
Rashan, Edrees H.
Eghbalian, Kian M.
Sivanand, Sharanya
Barbeau, Anna M. https://orcid.org/0000-0002-2382-4999
Riedmayr, Lisa M. https://orcid.org/0000-0002-0307-2507
Duquette, Mark
Ali, Ahmed
Henning, Nicole
Trojan, Sonia E. https://orcid.org/0000-0001-8876-6294
Waite, Millenia
Kunchok, Tenzin https://orcid.org/0000-0001-6603-4607
Nakano, Mayu A.
Gourgue, Florian https://orcid.org/0000-0001-9777-806X
Ferraro, Gino B.
Do, Brian T. https://orcid.org/0000-0003-4992-2623
Spanoudaki, Virginia
Sánchez-Rivera, Francisco J. https://orcid.org/0000-0002-8466-8563
Jin, Xin https://orcid.org/0000-0003-4167-1743
Church, George M. https://orcid.org/0000-0001-6232-9969
Jain, Rakesh K. https://orcid.org/0000-0001-7571-3548
Vander Heiden, Matthew G. https://orcid.org/0000-0002-6702-4192
- License Information
-
More Information
Article History
Received: 3 October 2024
Accepted: 11 November 2025
First Online: 7 January 2026
Competing interests
: R.F. consulted for Lime Therapeutics during this study, unrelated to the work presented. G.M.C. is a co-founder of Editas Medicine and has other financial interests listed in Supplementary Table . R.K.J. received consultant or scientific advisory board fees from DynamiCure, SPARC and SynDevRx; owns equity in Accurius, Enlight and SynDevRx; served on the Board of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund; and received research grants from Boehringer Ingelheim and Sanofi; no funding or reagents from these organizations were used in the study. M.G.V.H. discloses that he is or was a scientific advisor for Agios Pharmaceuticals, iTeos Therapeutics, Sage Therapeutics, Pretzel Therapeutics, Lime Therapeutics, Faeth Therapeutics, Droia Ventures, MPM Capital and Auron Therapeutics. All other authors declare no competing interests.
